<div id="readability-page-1"><div>&#34;As a Federal Lawsuit Challenges the CMS Cannabinoid Program, Questions Mount Over Safety Standards, Scientific Validation, and Patient Protections&#34; stated Duane Boise CEO MMJ International Holdings. WASHINGTON, DC / ACCESS Newswire / May 8, 2026 / A growing conflict between international scientific findings and U.S. healthcare policy is raising urgent questions about whether Medicare beneficiaries are being exposed to cannabinoid products that have not been proven safe.In March 2026, the European Food Safety Authority (EFSA) issued a formal scientific rejection of Charlottes Web hemp product submission concluding that the safety of a carbon dioxide extract derived from Cannabis sativa L. - including products associated with leading U.S. brands - &#34;cannot be established.&#34; <img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/imagelibrary/e8706bad-cf58-4a9b-bd81-b0d40ed5874c/1165523/mmjholding.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="300" height="240" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/imagelibrary/e8706bad-cf58-4a9b-bd81-b0d40ed5874c/1165523/mmjholding.png"/> That conclusion was not based on politics. It was based on data.According to EFSA, critical gaps included:<ul><li>Significant portions of the product remaining uncharacterized</li><li>Lack of reliable toxicological studies on the actual material</li><li>Absence of human clinical data</li><li>Unknown allergenicity and long-term safety profile</li></ul>The agency's bottom line was clear:The safety of the product could not be determined.Meanwhile in the United StatesAt nearly the same time, the Centers for Medicare &amp; Medicaid Services (CMS) launched the Substance Access Beneficiary Engagement Incentive (BEI) program.The initiative allows participating healthcare providers to discuss and furnish certain hemp, marijuana derived cannabinoid products to Medicare beneficiaries under Innovation Center authority.Unlike traditional drug pathways, the BEI program does not require approval from the U.S. Food and Drug Administration.That distinction is central to a federal lawsuit now pending:Smart Approaches to Marijuana (SAM), et al. v. Robert F. Kennedy Jr., et al. Case No. 1:26-cv-01081 (U.S. District Court for the District of Columbia)The Scientific GapUnder the FDA framework, products intended for therapeutic use typically undergo:<ul><li>Controlled clinical trials</li><li>Dose standardization</li><li>Safety and toxicology evaluation</li><li>Manufacturing and stability validation</li></ul>The BEI program operates outside that structure.While CMS has described the initiative as an innovation model, critics argue it effectively introduces products into federally funded care environments before those scientific benchmarks are met.Why This Matters for SeniorsMedicare beneficiaries represent one of the most medically complex populations in the healthcare system.Many patients:<ul><li>Take multiple medications (polypharmacy)</li><li>Have chronic conditions</li><li>Are more vulnerable to drug interactions</li></ul>Cannabinoid compounds, including THC, are known to interact with metabolic pathways such as CYP450 enzymes, which are involved in processing many common medications.Without controlled studies in this population, the full safety profile remains uncertain.Rapid Supply Chain ExpansionAt the same time the program launched, several companies publicly announced positioning within the emerging healthcare supply chain:<ul><li>Charlotte's Web highlighted alignment with CMS guidance</li><li>Cornbread Hemp announced institutional distribution through a national group purchasing organization</li></ul>These developments signal rapid commercialization of a category that has not undergone FDA drug approval review.A Regulatory TensionThe situation creates a notable contradiction:<ul><li>International regulators say safety cannot be established</li><li>The FDA has not approved these products as medicines</li><li>Yet a federal healthcare program is enabling access within Medicare-linked systems</li></ul>That tension is now at the center of federal litigation.What the Court Will DecideIn SAM v. Kennedy (1:26-cv-01081), the court is evaluating whether CMS exceeded its statutory authority by introducing cannabinoid furnishing pathways without:<ul><li>Formal rulemaking</li><li>Public notice and comment</li><li>FDA validation standards</li></ul>A ruling is expected to determine whether the program:<ul><li>Proceeds as implemented</li><li>Is narrowed or modified</li><li>Or is halted pending further review</li></ul>The Core QuestionThis debate ultimately comes down to a fundamental issue in healthcare policy:Should access to therapeutic products come before scientific validation- or should science remain the gatekeeper?Closing PerspectiveThe EFSA conclusion does not ban CBD products.But it does highlight a critical reality:The scientific evidence needed to establish safety is still incomplete.As federal policy evolves, the question is not whether innovation should occur-but whether it should occur before the science is fully understood, particularly for the nation's most vulnerable patients.CONTACT:Madison Hisey MHisey@mmjih.com 203-231-8583SOURCE: MMJ International HoldingsView the original press release on ACCESS Newswire <img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2NTUyMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2NTUyMw"/></div></div>

CWBHF

歐盟監管機構認為，Charlotte's Web 的大麻 CBD 產品的安全性 “無法確定”，原因是存在顯著的數據缺口。儘管如此，美國醫療保險和醫療補助服務中心（CMS）已啓動一項計劃，允許在沒有 FDA 批准的情況下向醫療保險受益人提供這些產品。這引發了對患者安全的擔憂，尤其是對於可能容易受到藥物相互作用影響的老年人。一項聯邦訴訟正在挑戰該計劃的合法性，質疑在科學驗證之前是否應允許獲取這些產品

歐盟監管機構稱 Charlotte's Web 大麻 CBD 的安全性 “無法確定”——那麼為什麼它會進入 Medicare？